Advertisement
Screener

TVARDI THERAPEUTICS, INC. (TVRD) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

TVARDI THERAPEUTICS, INC. Operating Cash Flow

TVARDI THERAPEUTICS, INC. (TVRD) reported Operating Cash Flow of -$15.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14

  • TVARDI THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$9.23M.
  • TVARDI THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$5.86M.
  • TVARDI THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.68M.
  • TVARDI THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.26M.
  • TVARDI THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$23.50M.
  • TVARDI THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$18.30M.
  • TVARDI THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$92.08M.
  • TVARDI THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$78.73M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$9.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$15.09M
10-Q · filed 2026-08-14
-$20.77M
derived: sum of 3 quarters · filed 2026-08-14
-$25.03M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$5.86M
10-Q · filed 2026-05-08
-$11.54M
derived: sum of 2 quarters · filed 2026-05-08
-$15.80M
derived: sum of 3 quarters · filed 2026-05-08
-$21.67M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$5.68M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$9.94M
derived: sum of 2 quarters · filed 2026-03-31
-$15.81M
derived: sum of 3 quarters · filed 2026-08-14
-$23.50M
10-K · filed 2026-03-31
2025-09-30-$4.26M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$10.13M
derived: sum of 2 quarters · filed 2026-08-14
-$17.81M
10-Q · filed 2025-11-13
-$22.65M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$5.87M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$13.56M
10-Q · filed 2026-08-14
-$18.39M
derived: sum of 3 quarters · filed 2026-08-14
-$25.05M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$7.69M
10-Q · filed 2026-05-08
-$4.69M
10-Q · filed 2025-05-13
-$12.52M
derived: sum of 2 quarters · filed 2026-05-08
-$19.18M
derived: sum of 3 quarters · filed 2026-05-08
$4.46M
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31-$4.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$11.49M
derived: sum of 2 quarters · filed 2026-03-31
$12.15M
derived: sum of 3 quarters · filed 2026-03-31
-$18.30M
10-K · filed 2026-03-31
-$60.92M
10-K · filed 2025-03-11
2024-09-30-$6.66M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$16.98M
derived: sum of 2 quarters · filed 2025-11-13
-$13.47M
10-Q · filed 2025-11-13
-$56.87M
10-Q · filed 2024-11-14
-$30.84M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$23.64M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
-$6.82M
10-Q · filed 2025-08-14
-$42.89M
10-Q · filed 2024-08-14
-$24.19M
derived: sum of 3 quarters · filed 2025-08-14
-$43.83M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$30.45M
10-Q · filed 2025-05-13
-$47.82M
derived: sum of 2 quarters · filed 2025-05-13
-$67.47M
derived: sum of 3 quarters · filed 2025-05-13
-$87.91M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$17.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
-$37.02M
derived: sum of 2 quarters · filed 2025-03-11
-$57.46M
derived: sum of 3 quarters · filed 2025-03-11
-$92.08M
10-K · filed 2025-03-11
2023-09-30-$19.64M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
-$40.09M
derived: sum of 2 quarters · filed 2024-11-14
-$74.71M
10-Q · filed 2024-11-14
-$98.22M
derived: sum of 4 quarters · filed 2025-03-11
2023-06-30-$20.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
-$55.06M
10-Q · filed 2024-08-14
-$78.57M
derived: sum of 3 quarters · filed 2025-03-11
-$103.77M
derived: sum of 4 quarters · filed 2025-03-11
2023-03-31-$34.62M
10-Q · filed 2024-05-13
-$58.13M
derived: sum of 2 quarters · filed 2025-03-11
-$83.32M
derived: sum of 3 quarters · filed 2025-03-11
-$87.82M
derived: sum of 4 quarters · filed 2025-03-11
2022-12-31-$23.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
-$48.70M
derived: sum of 2 quarters · filed 2025-03-11
-$53.20M
derived: sum of 3 quarters · filed 2025-03-11
-$78.73M
10-K · filed 2025-03-11
2022-09-30-$25.19M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$29.70M
derived: sum of 2 quarters · filed 2023-11-13
-$55.22M
10-Q · filed 2023-11-13
-$56.47M
derived: sum of 4 quarters · filed 2024-03-06
2022-06-30-$4.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
-$30.03M
10-Q · filed 2023-08-07
-$31.27M
derived: sum of 3 quarters · filed 2024-03-06
-$45.39M
derived: sum of 4 quarters · filed 2024-03-06
2022-03-31-$25.52M
10-Q · filed 2023-05-15
-$26.77M
derived: sum of 2 quarters · filed 2024-03-06
-$40.89M
derived: sum of 3 quarters · filed 2024-03-06
-$61.89M
derived: sum of 4 quarters · filed 2024-03-06
2021-12-31-$1.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06
-$15.36M
derived: sum of 2 quarters · filed 2024-03-06
-$36.37M
derived: sum of 3 quarters · filed 2024-03-06
-$60.09M
10-K · filed 2024-03-06
2021-09-30-$14.12M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
-$35.12M
derived: sum of 2 quarters · filed 2022-11-07
-$58.84M
10-Q · filed 2022-11-07
$23.25M
derived: sum of 4 quarters · filed 2023-03-06
2021-06-30-$21.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
-$44.73M
10-Q · filed 2022-08-08
$37.36M
derived: sum of 3 quarters · filed 2023-03-06
$15.74M
derived: sum of 4 quarters · filed 2023-03-06
2021-03-31-$23.72M
10-Q · filed 2022-05-09
$58.37M
derived: sum of 2 quarters · filed 2023-03-06
$36.75M
derived: sum of 3 quarters · filed 2023-03-06
$9.10M
derived: sum of 4 quarters · filed 2023-03-06
2020-12-31$82.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06
$60.47M
derived: sum of 2 quarters · filed 2023-03-06
$32.82M
derived: sum of 3 quarters · filed 2023-03-06
-$5.49M
10-K · filed 2023-03-06
2020-09-30-$21.62M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
-$49.27M
derived: sum of 2 quarters · filed 2021-11-08
-$87.58M
10-Q · filed 2021-11-08
-$118.74M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$27.65M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
-$65.95M
10-Q · filed 2021-08-09
-$97.12M
derived: sum of 3 quarters · filed 2022-03-01
-$122.76M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31-$38.30M
10-Q · filed 2021-05-10
-$69.47M
derived: sum of 2 quarters · filed 2022-03-01
-$95.11M
derived: sum of 3 quarters · filed 2022-03-01
-$120.00M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31-$31.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$56.80M
derived: sum of 2 quarters · filed 2022-03-01
-$81.70M
derived: sum of 3 quarters · filed 2022-03-01
-$109.22M
10-K · filed 2022-03-01
2019-09-30-$25.64M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
-$50.53M
derived: sum of 2 quarters · filed 2020-11-09
-$78.06M
10-Q · filed 2020-11-09
-$102.42M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30-$24.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
-$52.42M
10-Q · filed 2020-08-10
-$76.78M
derived: sum of 3 quarters · filed 2021-02-25
-$97.28M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31-$27.53M
10-Q · filed 2020-05-11
-$51.89M
derived: sum of 2 quarters · filed 2021-02-25
-$72.38M
derived: sum of 3 quarters · filed 2021-02-25
-$31.36M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31-$24.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
-$44.85M
derived: sum of 2 quarters · filed 2021-02-25
-$3.83M
derived: sum of 3 quarters · filed 2021-02-25
-$22.30M
10-K · filed 2021-02-25
2018-09-30-$20.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
$20.53M
derived: sum of 2 quarters · filed 2019-11-05
$2.06M
10-Q · filed 2019-11-05
-$9.35M
derived: sum of 4 quarters · filed 2020-02-27
2018-06-30$41.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
$22.55M
10-Q · filed 2019-08-07
$11.14M
derived: sum of 3 quarters · filed 2020-02-27
$1.29M
derived: sum of 4 quarters · filed 2020-02-27
2018-03-31-$18.47M
10-Q · filed 2019-05-07
-$29.88M
derived: sum of 2 quarters · filed 2020-02-27
-$39.73M
derived: sum of 3 quarters · filed 2020-02-27
2017-12-31-$11.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27
-$21.26M
derived: sum of 2 quarters · filed 2020-02-27
-$54.83M
10-K · filed 2020-02-27
2017-09-30-$9.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06
-$43.41M
10-Q · filed 2018-11-06
2017-06-30-$33.56M
10-Q · filed 2018-08-07
2016-12-31-$47.38M
10-K · filed 2019-03-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
MUSTANG BIO, INC. (MBIO)United States$0.013B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36